Paper30135355
Epigallocatechin-3-gallate and 6-OH-11-O-Hydroxyphenanthrene Limit BE(2)-C Neuroblastoma Cell Growth and Neurosphere Formation In Vitro.
Farabegoli F and 3 others. Nutrients, 2018. Cited by 9 papers, by iCite.
Cite this record
ConductScience Library. Epigallocatechin-3-gallate and 6-OH-11-O-Hydroxyphenanthrene Limit BE(2)-C Neuroblastoma Cell Growth and Neurosphere Formation In Vitro. Papers, record 30135355. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/30135355
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Epigallocatechin-3-gallate and 6-OH-11-O-Hydroxyphenanthrene Limit BE(2)-C Neuroblastoma Cell Growth and Neurosphere Formation In Vitro.
- PubMed
Topics14
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Catechin | Major topic |
| Neoplastic Stem Cells | Major topic |
| Neuroblastoma | Major topic |
| Phenanthrenes | Major topic |
| Apoptosis | |
| Cell Line, Tumor | |
| Cell Survival | |
| Drug Synergism | |
| Gene Expression Regulation, Neoplastic | |
| Genes, myc | |
| Humans | |
| Matrix Metalloproteinase 2 | |
| Matrix Metalloproteinase 9 | |
| Tea |
Source PubMed
References38
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 29062613 | Emerging and investigational therapies for neuroblastoma. | Expert Opin Orphan Drugs | 2017 | https://conductscience.org/library/papers/29062613 | PubMed |
| 2 | 20558371 | Recent advances in neuroblastoma. | N Engl J Med | 2010 | https://conductscience.org/library/papers/20558371 | PubMed |
| 3 | 24086065 | Neuroblastoma and MYCN. | Cold Spring Harb Perspect Med | 2013 | https://conductscience.org/library/papers/24086065 | PubMed |
| 4 | 25013807 | A RXR ligand 6-OH-11-O-hydroxyphenanthrene with antitumour properties enhances (-)-epigallocatechin-3-gallate activity in three human breast carcinoma cell lines. | Biomed Res Int | 2014 | https://conductscience.org/library/papers/25013807 | PubMed |
| 5 | 26534963 | The Metastasis Suppressor, N-MYC Downstream-regulated Gene-1 (NDRG1), Down-regulates the ErbB Family of Receptors to Inhibit Downstream Oncogenic Signaling Pathways. | J Biol Chem | 2016 | https://conductscience.org/library/papers/26534963 | PubMed |
| 6 | 19212680 | Retinoids induce differentiation and downregulate telomerase activity and N-Myc to increase sensitivity to flavonoids for apoptosis in human malignant neuroblastoma SH-SY5Y cells. | Int J Oncol | 2009 | https://conductscience.org/library/papers/19212680 | PubMed |
| 7 | 29764159 | Emerging role of immunotherapy for childhood cancers. | Chin Clin Oncol | 2018 | https://conductscience.org/library/papers/29764159 | PubMed |
| 8 | 20332466 | Epigenetic modifiers as anticancer drugs: effectiveness of valproic acid in neural crest-derived tumor cells. | Anticancer Res | 2010 | https://conductscience.org/library/papers/20332466 | PubMed |
| 9 | 19893570 | BH3 response profiles from neuroblastoma mitochondria predict activity of small molecule Bcl-2 family antagonists. | Cell Death Differ | 2010 | https://conductscience.org/library/papers/19893570 | PubMed |
| 10 | 12820415 | Effect of a new derivative of retinoic acid on proliferation and differentiation in human neuroblastoma cells. | Anticancer Res | 2003 | https://conductscience.org/library/papers/12820415 | PubMed |
| 11 | 21909813 | Epigallocatechin gallate inhibits sphere formation of neuroblastoma BE(2)-C cells. | Environ Health Prev Med | 2012 | https://conductscience.org/library/papers/21909813 | PubMed |
| 12 | 12880980 | Retinoid therapy of high-risk neuroblastoma. | Cancer Lett | 2003 | https://conductscience.org/library/papers/12880980 | PubMed |
| 13 | 28840597 | Retinoic acid postconsolidation therapy for high-risk neuroblastoma patients treated with autologous haematopoietic stem cell transplantation. | Cochrane Database Syst Rev | 2017 | https://conductscience.org/library/papers/28840597 | PubMed |
| 14 | 26729169 | Cancer Stem Cells and Their Interaction with the Tumor Microenvironment in Neuroblastoma. | Cancers (Basel) | 2015 | https://conductscience.org/library/papers/26729169 | PubMed |
| 15 | 28465354 | EGFR inhibition by (-)-epigallocatechin-3-gallate and IIF treatments reduces breast cancer cell invasion. | Biosci Rep | 2017 | https://conductscience.org/library/papers/28465354 | PubMed |
| 16 | 29445860 | Origin and initiation mechanisms of neuroblastoma. | Cell Tissue Res | 2018 | https://conductscience.org/library/papers/29445860 | PubMed |
| 17 | 22498172 | Alterations in expression of specific microRNAs by combination of 4-HPR and EGCG inhibited growth of human malignant neuroblastoma cells. | Brain Res | 2012 | https://conductscience.org/library/papers/22498172 | PubMed |
| 18 | 21796439 | A single-arm pilot phase II study of gefitinib and irinotecan in children with newly diagnosed high-risk neuroblastoma. | Invest New Drugs | 2012 | https://conductscience.org/library/papers/21796439 | PubMed |
| 19 | 22941525 | Retinoids in pediatric onco-hematology: the model of acute promyelocytic leukemia and neuroblastoma. | Adv Ther | 2012 | https://conductscience.org/library/papers/22941525 | PubMed |
| 20 | 16890796 | New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors. | Semin Oncol | 2006 | https://conductscience.org/library/papers/16890796 | PubMed |
Cited by8
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 9 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42764445 | A Hybrid Bioprinting-Microfabrication Approach to Controllable Multitype Spheroid Arrays for Modeling Tumor Heterogeneity. | Adv Healthc Mater | 2026 | https://conductscience.org/library/papers/42764445 | PubMed |
| 39804528 | Emerging Trends in Neuroblastoma Diagnosis, Therapeutics, and Research. | Mol Neurobiol | 2025 | https://conductscience.org/library/papers/39804528 | PubMed |
| 38243984 | The Potential of Epigallocatechin Gallate in Targeting Cancer Stem Cells: A Comprehensive Review. | Curr Med Chem | 2024 | https://conductscience.org/library/papers/38243984 | PubMed |
| 37450923 | MYC Oncogene: A Druggable Target for Treating Cancers with Natural Products. | Aging Dis | 2024 | https://conductscience.org/library/papers/37450923 | PubMed |
| 36677584 | Effects of Epigallocatechin-3-Gallate on Matrix Metalloproteinases in Terms of Its Anticancer Activity. | Molecules | 2023 | https://conductscience.org/library/papers/36677584 | PubMed |
| 36362917 | Nutraceutical Preventative and Therapeutic Potential in Neuroblastoma: From Pregnancy to Early Childhood. | Life (Basel) | 2022 | https://conductscience.org/library/papers/36362917 | PubMed |
| 31867574 | Cancer stem cells in neuroblastoma therapy resistance. | Cancer Drug Resist | 2019 | https://conductscience.org/library/papers/31867574 | PubMed |
| 31027187 | Tea in Health and Disease. | Nutrients | 2019 | https://conductscience.org/library/papers/31027187 | PubMed |
Genes16
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/30135355
GET https://conductscience.org/api/papers/v1/30135355/references?page=2